Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Other1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT05172258Phase 2Active Not Recruiting
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell Carcinoma+12 more
PrincipalinvestigatorStart date: 2022-07-26

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

George Blumenschein, MD

M.D. Anderson Cancer Center

Related
5 trials

Shared therapeutic areas:

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+3 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score12%

Douglas Adkins, M.D.

Washington University School of Medicine

Related
11 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and NeckMetastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Similarity Score6%

Mercedes Porosnicu, MD

Wake Forest University Health Sciences

Related
6 trials

Shared therapeutic areas:

Recurrent Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neck

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Douglas R Adkins, M.D.

Washington University School of Medicine

Related
7 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and NeckRecurrent Head and Neck Squamous Cell Carcinoma
Similarity Score4%

Vincent Chung

City of Hope Medical Center

Related
9 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and Neck

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Nina Bhardwaj, MD, PhD

Icahn School of Medicine at Mount Sinai

Related
8 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and Neck

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Dan Zandberg, MD

UPMC Hillman Cancer Center

Related
6 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and Neck
Similarity Score2%

Ezra Cohen, MD

University of Chicago

Related
6 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and Neck
Similarity Score2%

Ari Rosenberg, MD

University of Chicago

Related
5 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and Neck
Similarity Score2%

Jared Weiss, MD

University of North Carolina, Chapel Hill

Related
7 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and Neck
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT05172258Phase 2PrincipalInvestigator

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell Carcinoma+12 more
Active Not Recruiting

All 1 trials loaded